Elizabeth Crowley - 08 Dec 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
Sr. VP &CPDO
Signature
/s/ Samuel Martin, attorney in fact for Elizabeth Crowley
Issuer symbol
CLDX
Transactions as of
08 Dec 2021
Net transactions value
-$123,934
Form type
4
Filing time
10 Dec 2021, 15:02:59 UTC
Previous filing
03 Nov 2021
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $36,066 +4,000 +85% $9.02 8,726 08 Dec 2021 Direct F1
transaction CLDX Common Stock Sale $160,000 -4,000 -46% $40.00 4,726 08 Dec 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -4,000 -20% $0.000000 16,000 08 Dec 2021 Common Stock 4,000 $9.02 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
F2 The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021.
F3 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.